Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM).

Kaufmann TJ, Smits M, Boxerman J, Huang R, Barboriak DP, Weller M, Chung C, Tsien C, Brown PD, Shankar L, Galanis E, Gerstner E, van den Bent MJ, Burns TC, Parney IF, Dunn G, Brastianos PK, Lin NU, Wen PY, Ellingson BM.

Neuro Oncol. 2020 Feb 12. pii: noaa030. doi: 10.1093/neuonc/noaa030. [Epub ahead of print]

PMID:
32048719
2.

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.

Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group.

J Clin Oncol. 2019 May 1;37(13):1102-1110. doi: 10.1200/JCO.18.01100. Epub 2019 Mar 12.

PMID:
30860949
3.

Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities-Phase III Studies.

Gambhir SS, Shankar LK, Rosenthal E, Warram JM, Ghesani M, Hope TA, Jacobs PM, Jacobson GB, Wilson T, Siegel BA.

J Nucl Med. 2019 Jun;60(6):736-744. doi: 10.2967/jnumed.118.219824. Epub 2019 Mar 8. No abstract available.

4.

Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2019 Feb;21(1):191. doi: 10.1007/s11307-018-1287-7.

PMID:
30324461
5.

Inadvertent stent placement in the persistent hypoglossal artery: A case for caution.

Rao SS, Shankar L, Rajamani K.

Neurol India. 2018 May-Jun;66(3):828-830. doi: 10.4103/0028-3886.232348. No abstract available.

6.

Guidelines for quality control of PET/CT scans in a multicenter clinical study.

Hristova I, Boellaard R, Galette P, Shankar LK, Liu Y, Stroobants S, Hoekstra OS, Oyen WJG.

EJNMMI Phys. 2017 Sep 18;4(1):23. doi: 10.1186/s40658-017-0190-7.

7.

Immune Modulation Therapy and Imaging: Workshop Report.

Shields AF, Jacobs PM, Sznol M, Graham MM, Germain RN, Lum LG, Jaffee EM, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung DK, Wu AM, Sharon E, Shankar LK.

J Nucl Med. 2018 Mar;59(3):410-417. doi: 10.2967/jnumed.117.195610. Epub 2017 Aug 17.

8.

Evaluation of the Patient Health Questionnaire-2 as a Screening Tool for Depression during the Acute Stroke Admission.

Shankar L, Smith N, Uchino K, Thompson NR, Pozuelo L, Katzan IL.

J Stroke Cerebrovasc Dis. 2017 Nov;26(11):2519-2526. doi: 10.1016/j.jstrokecerebrovasdis.2017.05.044. Epub 2017 Jul 26.

PMID:
28756141
9.

Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.

Huang EP, Lin FI, Shankar LK.

Acad Radiol. 2017 Aug;24(8):1036-1049. doi: 10.1016/j.acra.2017.03.002. Epub 2017 Apr 26. Review.

10.

Using PET for therapy monitoring in oncological clinical trials: challenges ahead.

Deroose CM, Stroobants S, Liu Y, Shankar LK, Bourguet P.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):32-40. doi: 10.1007/s00259-017-3689-1. Epub 2017 Apr 27. Review.

PMID:
28451825
11.

Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer Detection.

Tummers WS, Warram JM, Tipirneni KE, Fengler J, Jacobs P, Shankar L, Henderson L, Ballard B, Pfefer TJ, Pogue BW, Weichert JP, Bouvet M, Sorger J, Contag CH, Frangioni JV, Tweedle MF, Basilion JP, Gambhir SS, Rosenthal EL.

Cancer Res. 2017 May 1;77(9):2197-2206. doi: 10.1158/0008-5472.CAN-16-3217. Epub 2017 Apr 20. Erratum in: Cancer Res. 2018 Feb 15;78(4):1123.

12.

Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.

Lin FI, Huang EP, Shankar LK.

Acad Radiol. 2017 Aug;24(8):1027-1035. doi: 10.1016/j.acra.2016.11.024. Epub 2017 Apr 11. Review.

13.

Performance Observations of Scanner Qualification of NCI-Designated Cancer Centers: Results From the Centers of Quantitative Imaging Excellence (CQIE) Program.

Rosen M, Kinahan PE, Gimpel JF, Opanowski A, Siegel BA, Hill GC, Weiss L, Shankar L.

Acad Radiol. 2017 Feb;24(2):232-245. doi: 10.1016/j.acra.2016.09.025. Epub 2016 Nov 29.

14.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

15.

Qualification of National Cancer Institute-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials.

Scheuermann JS, Reddin JS, Opanowski A, Kinahan PE, Siegel BA, Shankar LK, Karp JS.

J Nucl Med. 2017 Jul;58(7):1065-1071. doi: 10.2967/jnumed.116.186759. Epub 2017 Mar 2. Review.

16.

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL.

EJNMMI Res. 2017 Dec;7(1):8. doi: 10.1186/s13550-017-0258-3. Epub 2017 Jan 19.

17.

Clinical Translation of the National Institutes of Health's Investments in Nanodrug Products and Devices.

Henderson LA, Shankar LK.

AAPS J. 2017 Mar;19(2):343-359. doi: 10.1208/s12248-016-9995-x. Epub 2016 Dec 19. Review.

PMID:
27995455
18.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

19.

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E.

Eur J Cancer. 2016 Jul;62:138-45. doi: 10.1016/j.ejca.2016.03.082. Epub 2016 May 26. Review.

20.

Hippocampal Neurometabolite Changes in Hypothyroidism: An In Vivo (1) H Magnetic Resonance Spectroscopy Study Before and After Thyroxine Treatment.

Singh S, Rana P, Kumar P, Shankar LR, Khushu S.

J Neuroendocrinol. 2016 Sep;28(9). doi: 10.1111/jne.12399.

PMID:
27203419
21.

RECIST 1.1-Update and clarification: From the RECIST committee.

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L.

Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.

22.

Imaging and Data Acquisition in Clinical Trials for Radiation Therapy.

FitzGerald TJ, Bishop-Jodoin M, Followill DS, Galvin J, Knopp MV, Michalski JM, Rosen MA, Bradley JD, Shankar LK, Laurie F, Cicchetti MG, Moni J, Coleman CN, Deye JA, Capala J, Vikram B.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):404-11. doi: 10.1016/j.ijrobp.2015.10.028. Epub 2015 Oct 24. Review.

23.

A risk management approach for imaging biomarker-driven clinical trials in oncology.

Liu Y, deSouza NM, Shankar LK, Kauczor HU, Trattnig S, Collette S, Chiti A.

Lancet Oncol. 2015 Dec;16(16):e622-8. doi: 10.1016/S1470-2045(15)00164-3. Review.

PMID:
26678215
24.

Insecticide susceptibility of Phlebotomus argentipes & assessment of vector control in two districts of West Bengal, India.

Kumar V, Shankar L, Kesari S, Bhunia GS, Dinesh DS, Mandal R, Das P.

Indian J Med Res. 2015 Aug;142(2):211-5. doi: 10.4103/0971-5916.164260.

25.

Which Comorbidities and Complications Predict Ischemic Stroke Recovery and Length of Stay?

Mohamed W, Bhattacharya P, Shankar L, Chaturvedi S, Madhavan R.

Neurologist. 2015 Aug;20(2):27-32. doi: 10.1097/NRL.0000000000000040.

PMID:
26280287
26.

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee.

Neuro Oncol. 2015 Sep;17(9):1188-98. doi: 10.1093/neuonc/nov095. Epub 2015 Aug 5. Review.

27.

Alterations of Functional Connectivity Among Resting-State Networks in Hypothyroidism.

Singh S, Kumar M, Modi S, Kaur P, Shankar LR, Khushu S.

J Neuroendocrinol. 2015 Jul;27(7):609-15. doi: 10.1111/jne.12282.

PMID:
25855375
28.

Reply to Verlingue, Koscielny and Ferté.

Litière S, De Vries EG, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST committee.

Eur J Cancer. 2014 Nov;50(16):2889-91. doi: 10.1016/j.ejca.2014.08.001. Epub 2014 Sep 15. No abstract available.

PMID:
25219450
29.

Diffusion tensor tractography in hypothyroidism and its correlation with memory function.

Singh S, Trivedi R, Singh K, Kumar P, Shankar LR, Khushu S.

J Neuroendocrinol. 2014 Nov;26(11):825-33. doi: 10.1111/jne.12193.

PMID:
25131823
30.

The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals.

Clarke LP, Nordstrom RJ, Zhang H, Tandon P, Zhang Y, Redmond G, Farahani K, Kelloff G, Henderson L, Shankar L, Deye J, Capala J, Jacobs P.

Transl Oncol. 2014 Feb 1;7(1):1-4. eCollection 2014 Feb.

31.

Are we ready for the 10% solution?

Chen HX, Rubinstein LV, Shankar LK, Abrams JS.

Oncologist. 2014 May;19(5):439-40. doi: 10.1634/theoncologist.2014-0126. Epub 2014 Apr 22. No abstract available.

32.

The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.

Litière S, de Vries EGE, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST Committee.

Eur J Cancer. 2014 Jul;50(10):1847-1853. doi: 10.1016/j.ejca.2014.03.014. Epub 2014 Apr 10.

PMID:
24726734
33.

The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community.

Liu Y, Litière S, de Vries EG, Sargent D, Shankar L, Bogaerts J, Seymour L.

Eur J Cancer. 2014 Jan;50(2):260-6. doi: 10.1016/j.ejca.2013.10.011. Epub 2013 Nov 13.

PMID:
24239447
34.

A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2014 Jun;16(3):431-40. doi: 10.1007/s11307-013-0699-7. Epub 2013 Oct 30. Erratum in: Mol Imaging Biol. 2019 Feb;21(1):191.

35.

The clinical evaluation of novel imaging methods for cancer management.

Shankar LK.

Nat Rev Clin Oncol. 2012 Dec;9(12):738-44. doi: 10.1038/nrclinonc.2012.186. Epub 2012 Nov 13. Review.

PMID:
23149888
36.

Voxel-based morphometric analysis in hypothyroidism using diffeomorphic anatomic registration via an exponentiated lie algebra algorithm approach.

Singh S, Modi S, Bagga D, Kaur P, Shankar LR, Khushu S.

J Neuroendocrinol. 2013 Mar;25(3):229-34. doi: 10.1111/jne.12001.

PMID:
23057474
37.

Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis.

de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, Boers M, Smit EF, Stroobants S, Weber WA, Hoekstra OS.

J Nucl Med. 2012 May;53(5):701-8. doi: 10.2967/jnumed.111.095299. Epub 2012 Apr 10.

38.

Multiplexed detection and differentiation of the DNA strains for influenza A (H1N1 2009) using a silicon-based microfluidic system.

Kao LT, Shankar L, Kang TG, Zhang G, Tay GK, Rafei SR, Lee CW.

Biosens Bioelectron. 2011 Jan 15;26(5):2006-11. doi: 10.1016/j.bios.2010.08.076. Epub 2010 Sep 9.

PMID:
20888214
39.

Clinical profiles, complications, and disability in cocaine-related ischemic stroke.

Bhattacharya P, Taraman S, Shankar L, Chaturvedi S, Madhavan R.

J Stroke Cerebrovasc Dis. 2011 Sep-Oct;20(5):443-9. doi: 10.1016/j.jstrokecerebrovasdis.2010.02.017. Epub 2010 Sep 2.

PMID:
20813550
40.

Comparison of outcomes of nonsurgical spontaneous intracerebral hemorrhage based on risk factors and physician specialty.

Bhattacharya P, Shankar L, Manjila S, Chaturvedi S, Madhavan R.

J Stroke Cerebrovasc Dis. 2010 Sep-Oct;19(5):340-6. doi: 10.1016/j.jstrokecerebrovasdis.2009.07.009. Epub 2010 May 23.

PMID:
20547074
41.

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR; Biomarkers Task Force of the NCI Investigational Drug Steering Committee.

Clin Cancer Res. 2010 Mar 15;16(6):1745-55. doi: 10.1158/1078-0432.CCR-09-2167. Epub 2010 Mar 9.

42.

Improving cancer outcomes through international collaboration in academic cancer treatment trials.

Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacombe D, Parmar M, Seibel N, Shankar L, Swart AM, Therasse P, Vikram B, von Frenckell R, Friedlander M, Fujiwara K, Kaplan RS, Meunier F.

J Clin Oncol. 2009 Oct 20;27(30):5109-14. doi: 10.1200/JCO.2009.22.5771. Epub 2009 Aug 31. Review.

43.

WITHDRAWN: Clinical and echocardiographic predictors of cerebrovascular events and left ventricular thrombus in patients with severe systolic dysfunction in sinus rhythm.

Mahajan N, Madhavan R, Bhattacharya P, Batra S, Ganguly J, Simegn M, Shankar L, Ramappa P, Chaturvedi S, Afonso L.

J Neurol Sci. 2009 Aug 8. [Epub ahead of print]

PMID:
19665734
44.

Predictors of stroke in patients with severe systolic dysfunction in sinus rhythm: role of echocardiography.

Mahajan N, Ganguly J, Simegn M, Bhattacharya P, Shankar L, Madhavan R, Chaturvedi S, Ramappa P, Afonso L.

Int J Cardiol. 2010 Nov 5;145(1):87-9. doi: 10.1016/j.ijcard.2009.05.039. Epub 2009 Jun 10.

PMID:
19520443
45.

NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA.

Mol Imaging Biol. 2009 Sep-Oct;11(5):343-55. doi: 10.1007/s11307-009-0215-2. Epub 2009 Mar 27.

46.

Considerations for the use of imaging tools for phase II treatment trials in oncology.

Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ.

Clin Cancer Res. 2009 Mar 15;15(6):1891-7. doi: 10.1158/1078-0432.CCR-08-2030. Epub 2009 Mar 10. Review.

47.

Lessons learned from independent central review.

Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

PMID:
19101138
48.

Recommendations for the assessment of progression in randomised cancer treatment trials.

Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M, Rubinstein L, Schwartz LH, Shankar L, Therasse P.

Eur J Cancer. 2009 Jan;45(2):281-9. doi: 10.1016/j.ejca.2008.10.042.

PMID:
19097775
49.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.

Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.

PMID:
19097774
50.

Evaluation of lymph nodes with RECIST 1.1.

Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, Eisenhauer EA.

Eur J Cancer. 2009 Jan;45(2):261-7. doi: 10.1016/j.ejca.2008.10.028. Epub 2008 Dec 16.

PMID:
19091550

Supplemental Content

Loading ...
Support Center